Abstract
The increasing number of transgenic or gene knockout mouse models generated for use in drug metabolism studies has meant that a greater understanding of the function and substrate specificities of murine cytochromes P450 (P450s) has become essential, particularly with the recent advances in “humanized” mouse models. In this study, we have heterologously expressed nine murine P450s—Cyp1a1, Cyp1a2, Cyp1b1, Cyp2a4, Cyp2b20, Cyp2c29, Cyp2d22, Cyp2e1, and Cyp3a11—individually with human P450 oxidoreductase to generate functional monooxygenase systems in Escherichia coli. We have identified a suitable fluorogenic probe for each P450 and determined the apparent kinetic parameters. These probes have enabled the screening of a panel of 31 test compounds classified as “drugs,” “natural compounds,” “endogenous compounds,” and “pesticides” by measurement of IC50, thus allowing the comparison of binding affinities. Human P450s CYP2C9, CYP2D6, and CYP3A4 were also included in the study to enable direct comparisons to be made with the mouse enzymes. Although there were general similarities between human and mouse P450s, perhaps the most significant finding in this study was the observation that, despite 77% amino acid identity, Cyp2d22 and CYP2D6 were remarkably dissimilar in a range of enzymatic properties, with potentially serious implications for pharmacokinetic studies using CYP2D substrates. The data presented in this study provide a solid foundation with which to assess the degree of similarity (or difference) between mouse and human P450s involved in xenobiotic metabolism and can be used as a basis for further studies.
Footnotes
-
C.R.W. is funded by a Programme Grant Award from Cancer Research UK.
-
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
-
doi:10.1124/dmd.108.021261.
-
ABBREVIATIONS: P450, cytochrome P450; AMMC, 3-[2-(N,N-diethyl-N-methylammonium)-ethyl]-7-methoxy-4-methylcoumarin; BFC, 7-benzyloxy-4-trifluoromethylcoumarin; BQ, 7-benzyloxyquinoline; BR, benzyloxyresorufin; cc, correlation coefficient; ER, ethoxyresorufin; DBF, dibenzyl fluorescein; MFC, 7-methoxy-4-trifluoromethylcoumarin; MR, methoxyresorufin; POR, P450 oxidoreductase; PR, pentoxyresorufin; RT-PCR, reverse transcriptase-polymerase chain reaction; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid.
-
↵
The online version of this article (available at http://dmd.aspetjournals.org) contains supplemental material.
-
↵1 Current affiliation: Biochemistry and Biophysics Group, Pharmacokinetics and Drug Metabolism, Amgen, Inc., Seattle, WA.
- Received March 3, 2008.
- Accepted April 16, 2008.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|